Analysis of HRD and Replication Stress Therapies from Clinical Trials Data

A 25.1 MB collection by Tugba Y. Ozmen, last updated in April 2026, investigates assays for homologous recombination deficiency and replication stress in cancer. The work includes a comparative pan-cancer analysis of therapy efficacy and toxicity based on results from clinicaltrials.gov. It explores the integration of these pathways with immune contexture to inform next-generation treatment strategies.

Use Cases

• Compare the efficacy of PARP inhibitors, replication stress, and immune checkpoint blockade therapies based on the described pan-cancer analysis.
• Investigate the interaction between homologous recombination deficiency and replication stress pathways as discussed in the description.
• Assess the toxicity profiles of combination cancer therapies based on the analysis of clinical trial results.
• Explore the potential of a unified therapeutic axis integrating HRD, RS, and immune contexture for guiding treatment strategies.

Strengths

• Includes analysis from clinicaltrials.gov, a major repository for clinical trial information.
• Released under a permissive CC-BY-4.0 license, facilitating reuse and sharing.
• Last updated date is explicitly provided as 2026-04-26.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The 25.1 MB size suggests a relatively small dataset, potentially limiting analysis scope.

Provenance

Source

figshare

Collection Method

Analysis of results available on clinicaltrials.gov, as stated in the description.

Freshness

Last updated 2026-04-26 19:40:05; freshness should be verified.